Nutcracker Therapeutics is an RNA therapeutics company developing mRNA medicines alongside a proprietary biochip-based manufacturing platform. The platform combines RNA biochemistry with microfluidic engineering, semiconductor-like biochips, and a proprietary nanoparticle delivery technology to enable a fully automated, isolated "GMP-in-a-box" manufacturing pathway. It is designed to support therapeutic development from discovery through clinic and commercialization, scaling appropriately at each stage. The company has a wholly owned pipeline of RNA therapeutic programs and established partnership initiatives with clinical investigators at several leading institutions. Nutcracker plans to expand and advance its pipeline of mRNA medicines for cancer and further refine its RNA manufacturing platform and underlying technology. The company announced a $167 million Series C to support these efforts. Nutcracker Therapeutics develops and produces mRNA therapeutics on a proprietary microfluidic, biochip-based platform called ACORN. The ACORN platform is a computer-controlled RNA manufacturing system that starts with a nucleic acid sequence and produces optimized nanoparticle-encapsulated RNA therapeutics on dedicated, single-use biochips. The company combines the productivity of RNA biology with innovations inspired by semiconductor manufacturing techniques to enable rapid discovery, development and manufacturing of mRNA therapies and vaccines. Nutcracker is led by co-founder and CEO Igor Khandros, Ph.D., who previously founded FormFactor and Berkeley Lights. The company is based in Emeryville, California. It raised $60M in a Series B to continue to expand its development efforts.

Total raised

$227M

Funding rounds

2

Latest round

Series C

Latest activity

Mar 2022